Truist raised the firm’s price target on Tenet Healthcare (THC) to $240 from $225 and keeps a Buy rating on the shares. The firm is updating its model after the company’s Q3 earnings beat and guidance raise, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $235 from $225 at Mizuho
- Tenet Healthcare price target raised to $252 from $230 at RBC Capital
- Tenet Healthcare’s Q3 2025 Earnings Call Highlights Strong Growth
- Tenet Healthcare: Strong Performance and Positive Outlook Drive Buy Rating
- Tenet Healthcare price target raised to $250 from $200 at Raymond James